DCOY
Decoy Therapeutics Inc.Healthcare · $1M market cap
Verdict
We can't put a fair value on DCOY right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.
Business quality
1 of 5 clear the 10% bar. What are the Big Five?
Follow DCOY
Track it on your watchlist and see the full analysis. Free.
Create a free accountInsider activity
Since Aug 31, 2026: no open-market purchases and 10 other filings (stock awards, tax withholding and similar). Why purchases matter
Other filings
Gauthier Patricia G.
director · 2026-08-31
Award
2,000 shares
McVicar William K.
director · 2026-08-31
Award
3,000 shares
Lammers Paul
director · 2026-08-31
Award
2,000 shares
HANISH ARNOLD C
director · 2026-08-31
Award
3,000 shares
Hibner Barbara Louise
Chief Scientific Officer · 2026-08-31
Award
4,216 shares
Show all 10 other filingsShow fewer
Rosenblum Mark J
Chief Financial Officer · 2026-08-31
Award
9,682 shares
Marschel Peter Klaus
Chief Business Officer · 2026-08-31
Award
3,900 shares
PIERCE FREDERICK II
Chief Executive Officer · 2026-08-31
Award
33,455 shares
Lieber Jonathan I
director · 2026-08-31
Award
2,000 shares
Burleson Tess
director · 2026-08-31
Award
2,000 shares
About Decoy Therapeutics Inc.
Based in Cambridge, Massachusetts, Decoy Therapeutics Inc. is an early-stage biotechnology firm dedicated to tackling critical unmet medical needs. The company employs cutting-edge machine learning and AI technologies, alongside accelerated synthesis methods, to swiftly design, engineer, and manufacture innovative peptide conjugate drug candidates.
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works